Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) | Starlite/ChEMBL | References |
Homo sapiens | integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus multilocularis | integrin alpha 3 | integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) | 1032 aa | 873 aa | 22.0 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | nuclear receptor nhr-7B | 0.0723 | 0.2643 | 0.1985 |
Onchocerca volvulus | 0.2117 | 1 | 1 | |
Loa Loa (eye worm) | hexokinase | 0.0655 | 0.2282 | 0.1592 |
Loa Loa (eye worm) | hexokinase type II | 0.2117 | 1 | 1 |
Brugia malayi | hexokinase type II | 0.0673 | 0.2377 | 0.1696 |
Entamoeba histolytica | hexokinase 2 | 0.2117 | 1 | 0.5 |
Onchocerca volvulus | Hexokinase homolog | 0.1328 | 0.5835 | 0.4266 |
Trypanosoma brucei | hexokinase | 0.2117 | 1 | 0.5 |
Schistosoma mansoni | hexokinase | 0.2117 | 1 | 1 |
Echinococcus granulosus | hexokinase | 0.2117 | 1 | 1 |
Leishmania major | hexokinase, putative | 0.2117 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.2117 | 1 | 1 |
Echinococcus multilocularis | hexokinase type 2 | 0.2117 | 1 | 1 |
Trypanosoma cruzi | hexokinase, putative | 0.2117 | 1 | 0.5 |
Onchocerca volvulus | 0.2117 | 1 | 1 | |
Echinococcus multilocularis | hexokinase | 0.2117 | 1 | 1 |
Treponema pallidum | hexokinase (hxk) | 0.2117 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0708 | 0.256 | 0.1894 |
Toxoplasma gondii | hexokinase | 0.2117 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0673 | 0.2377 | 0.1696 |
Loa Loa (eye worm) | hexokinase | 0.2117 | 1 | 1 |
Trypanosoma cruzi | hexokinase, putative | 0.2117 | 1 | 0.5 |
Onchocerca volvulus | 0.1328 | 0.5835 | 0.4266 | |
Trypanosoma brucei | hexokinase | 0.2117 | 1 | 0.5 |
Echinococcus granulosus | hexokinase type 2 | 0.2117 | 1 | 1 |
Brugia malayi | Hexokinase family protein | 0.2117 | 1 | 1 |
Loa Loa (eye worm) | hexokinase | 0.1328 | 0.5835 | 0.5463 |
Loa Loa (eye worm) | hexokinase | 0.2117 | 1 | 1 |
Echinococcus granulosus | hexokinase | 0.2117 | 1 | 1 |
Echinococcus multilocularis | hexokinase | 0.2117 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0673 | 0.2377 | 0.1696 |
Loa Loa (eye worm) | hypothetical protein | 0.1444 | 0.6447 | 0.6129 |
Leishmania major | hexokinase, putative | 0.2117 | 1 | 0.5 |
Onchocerca volvulus | 0.2117 | 1 | 1 | |
Entamoeba histolytica | hexokinase 1 | 0.2117 | 1 | 0.5 |
Brugia malayi | Hexokinase family protein | 0.1328 | 0.5835 | 0.5463 |
Brugia malayi | nuclear hormone receptor | 0.0723 | 0.2643 | 0.1985 |
Brugia malayi | Hexokinase family protein | 0.0655 | 0.2282 | 0.1592 |
Trypanosoma brucei | hexokinase, putative | 0.2117 | 1 | 0.5 |
Plasmodium vivax | hexokinase, putative | 0.2117 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.2117 | 1 | 1 |
Plasmodium falciparum | hexokinase | 0.2117 | 1 | 0.5 |
Schistosoma mansoni | integrin alpha-4 | 0.0472 | 0.1316 | 0.1316 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 60 nM | Inhibition of very late antigen 4 from HL60 lysate in a protein-based ligand binding assay | ChEMBL. | 12039570 |
IC50 (binding) | = 60 nM | Inhibition of very late antigen 4 from HL60 lysate in a protein-based ligand binding assay | ChEMBL. | 12039570 |
IC50 (binding) | = 3400 nM | Inhibition of very late antigen 4 expressed in Jurkat cell line, in a cell-based adhesion assay | ChEMBL. | 12039570 |
IC50 (binding) | = 3400 nM | Inhibition of very late antigen 4 expressed in Jurkat cell line, in a cell-based adhesion assay | ChEMBL. | 12039570 |
k (ADMET) | 0 hr-1 | Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined | ChEMBL. | 12039570 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.